ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1086

Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus

Zhaoyun Liang1, Xiaona Jing1, Meihua Hao1, Chong Gao2, Xiao-Feng Li3 and Junwei Chen1, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 3Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: interleukins (IL) and systemic lupus erythematosus (SLE), T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease. Regulatory T (Treg) cells and T helper type 17 (Th17) cells play opposite roles in immune tolerance and autoimmune diseases. It was reported previously that elevated Th17 and/or decreased Treg cells caused an imbalance of Treg/Th17 in SLE. Since low-dose IL-2 can selectively stimulate the differentiation of CD4+Treg cells and rapamycin can promote the proliferation of Treg cells and inhibits differentiation of Th17 cells, the combined treatment of the low-dose IL-2 and rapamycin may increase the remission rate of SLE.

Methods: Sixty-six refractory SLE patients (53 women and 3 men), with an average course of 74.22±40.91 months and average age of 33.10±11.72 years, were enrolled. They fulfilled the 1997 ACR criteria and had been treating with glucocorticoid and immunosuppressant for more than one year, but had not yet reached the disease remission. The standard for remission is defined as meeting all the following conditions: sustained remission of clinical symptoms, no organ damage indication, normal inflammatory index and normal immune function. The eligible patients were given IL-2 and rapamycin in combination with conventional therapy. At 0, 6, 12, 24 week respectively after medication, the absolute numbers of Th17 cells and Treg cells in blood were examined by flow cytometry. Also, the clinical symptoms, blood routine, urine routine, ESR, the dosage of corticosteroids and immunosuppressant, or the remission rate was registered respectively.

Results: As compared with healthy controls, the absolute number of Treg cells in the patients with refractory SLE significantly decreased, whereas that of Th17 cells did not increase clearly. At 24 week after treatment with low-dose IL-2 combined with rapamycin, 36.0% of patients with refractory SLE achieved remission, accompanying increase in the absolute numbers of peripheral Treg cells from a median of 17.08 cells/µl (at week 0) to 28.16 cells/µl (at week 24) (P=0.002). Accordingly, he ratio of Th17/Treg cells showed a reduction from a median of 0.87 at week 0 to 0.31 at week 24 (P=0.019), indicating a restored balance of them. No significant difference was observed in the absolute numbers of Th17 after combined treatment. At week 24, the mean dosage of prednisone used in refractory SLE patients was decreased from 17.19 mg/d to 9.11 mg/d. And the categories of immunosuppressant used were also reduced (P<0.05).

Conclusion: Our findings indicate that refractory SLE is associated with the decreased absolute number of Treg cells but not increased Th17 cells in blood. Low-dose IL-2 combined with rapamycin treatment can restore the balance of Th17 and Treg cells in refractory SLE due to the significant increase in Treg cells. This therapy can induce higher remission rate of the patients after 24-week treatment and reduce the usage of glucocorticoid and immunosuppressant.


Disclosure: Z. Liang, None; X. Jing, None; M. Hao, None; C. Gao, None; X. F. Li, None; J. Chen, None.

To cite this abstract in AMA style:

Liang Z, Jing X, Hao M, Gao C, Li XF, Chen J. Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-dose-il-2-combined-with-rapamycin-efficiently-promotes-remission-of-refractory-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-il-2-combined-with-rapamycin-efficiently-promotes-remission-of-refractory-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology